PriceTargets.com logo

NASDAQ:SIEN - Sientra Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.75
  • Forecasted Upside: 66.04 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.87 As of 10/20/2021 01:00 AM ET
▲ +0.11 (1.91%)

This chart shows the closing price for SIEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sientra Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SIEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SIEN

Analyst Price Target is $9.75
▲ +66.04% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sientra in the last 3 months. The average price target is $9.75, with a high forecast of $11.00 and a low forecast of $8.24. The average price target represents a 66.04% upside from the last price of $5.87.

This chart shows the closing price for SIEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Sientra. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/14/2021SVB LeerinkSet Price TargetBuy$8.24Low
5/18/2021Canaccord GenuityBoost Price TargetBuy$9.00 ➝ $10.00N/A
5/12/2021SVB LeerinkBoost Price TargetOutperform$10.00 ➝ $11.00High
5/12/2021Canaccord GenuityReiterated RatingBuy$9.00 ➝ $10.00High
3/12/2021Canaccord GenuityBoost Price TargetBuy$8.00 ➝ $9.00Medium
3/12/2021SVB LeerinkBoost Price TargetOutperform$8.00 ➝ $10.00High
2/5/2021Maxim GroupReiterated RatingBuy$11.00High
2/5/2021Canaccord GenuityBoost Price TargetBuy$6.00 ➝ $8.00High
11/10/2020William BlairReiterated RatingOutperformLow
11/10/2020SVB LeerinkBoost Price TargetOutperform$6.00 ➝ $8.00High
8/14/2020Canaccord GenuityReiterated RatingBuy$6.00High
8/12/2020Maxim GroupReiterated RatingBuy$8.00High
8/11/2020SVB LeerinkBoost Price TargetOutperform$5.30 ➝ $6.00High
6/11/2020Maxim GroupBoost Price Target$5.00 ➝ $8.00Low
5/15/2020Canaccord GenuityLower Price TargetBuy$9.00 ➝ $5.00Medium
5/12/2020SVB LeerinkLower Price TargetOutperform$6.50 ➝ $5.30High
3/23/2020StephensLower Price TargetOverweight$10.00 ➝ $5.00High
3/12/2020Craig HallumLower Price TargetBuy$14.00 ➝ $9.00High
3/12/2020SVB LeerinkLower Price TargetOutperform$13.00 ➝ $6.50High
3/12/2020Canaccord GenuityLower Price TargetBuy$13.00 ➝ $9.00High
3/12/2020Maxim GroupLower Price TargetBuy$12.00 ➝ $8.00High
3/12/2020StephensLower Price TargetOverweight$14.00 ➝ $10.00High
11/5/2019William BlairUpgradeMarket Perform ➝ OutperformMedium
9/24/2019Canaccord GenuitySet Price TargetBuy$13.00High
8/9/2019StephensSet Price TargetBuy$16.00Low
8/9/2019Canaccord GenuityBoost Price TargetBuy$11.00 ➝ $13.00N/A
8/9/2019Maxim GroupReiterated RatingBuy ➝ Buy$16.00 ➝ $12.00High
7/25/2019Craig HallumLower Price TargetBuy$20.00 ➝ $14.00Medium
6/5/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$8.00 ➝ $10.00High
4/22/2019Craig HallumSet Price TargetBuy$23.00Low
3/26/2019Craig HallumSet Price TargetBuy$23.00High
3/14/2019Wells Fargo & CompanyInitiated CoverageMarket Perform$9.00High
3/13/2019Stifel NicolausLower Price TargetBuy$19.00 ➝ $16.00Medium
3/13/2019Dougherty & CoLower Price TargetBuy$29.00 ➝ $27.00High
3/13/2019SVB LeerinkLower Price Target$22.00 ➝ $18.00High
3/13/2019William BlairDowngradeOutperform ➝ Market PerformHigh
2/11/2019Maxim GroupReiterated RatingBuy$20.00Medium
12/19/2018Maxim GroupUpgradeHold ➝ BuyLow
8/30/2018Dougherty & CoInitiated CoverageBuy ➝ Buy$31.00Medium
8/9/2018StephensReiterated RatingBuy$30.00High
8/8/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$21.00 ➝ $25.00High
8/8/2018Canaccord GenuityBoost Price TargetBuy$19.00 ➝ $25.00High
6/4/2018Craig HallumInitiated CoverageBuy$23.00High
5/10/2018Canaccord GenuityReiterated RatingBuy$19.00High
4/27/2018Lake Street CapitalUpgradeHold ➝ Buy$16.00Low
4/26/2018Maxim GroupBoost Price TargetBuy ➝ Buy$15.00 ➝ $19.00Low
4/20/2018SVB LeerinkReiterated RatingOutperformHigh
4/19/2018Canaccord GenuityReiterated RatingBuy$18.00High
4/19/2018Lake Street CapitalBoost Price TargetHold ➝ Hold$11.00 ➝ $13.00High
3/22/2018Maxim GroupInitiated CoverageBuy ➝ Buy$15.00High
3/14/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$19.00 ➝ $18.00Low
3/1/2018William BlairReiterated RatingBuyLow
2/21/2018Lake Street CapitalDowngradeBuy ➝ Hold$15.00 ➝ $11.00High
1/19/2018Stifel NicolausUpgradeHold ➝ Buy$14.00High
1/5/2018Canaccord GenuityReiterated RatingBuy$19.00High
10/8/2017Canaccord GenuityReiterated RatingBuy$14.00N/A
9/27/2017Stifel NicolausReiterated RatingHold ➝ Hold$11.00 ➝ $14.00High
9/13/2017William BlairUpgradeMarket Perform ➝ OutperformHigh
8/28/2017Canaccord GenuityInitiated CoverageBuy ➝ Buy$14.00High
8/8/2017Lake Street CapitalReiterated RatingBuy$11.00 ➝ $15.00Low
8/2/2017Lake Street CapitalReiterated RatingBuy ➝ Buy$11.00 ➝ $15.00High
7/11/2017StephensInitiated CoverageOverweight$12.00High
4/17/2017Lake Street CapitalInitiated CoverageBuy ➝ Buy$11.00High
(Data available from 10/21/2016 forward)

News Sentiment Rating

-0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2021
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/22/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2021
  • 1 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
10/21/2021

Current Sentiment

  • 1 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Sientra logo
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini on August 29, 2003 and is headquartered in Santa Barbara, CA.
Read More

Today's Range

Now: $5.87
Low: $5.60
High: $5.95

50 Day Range

MA: $6.01
Low: $5.33
High: $7.09

52 Week Range

Now: $5.87
Low: $3.80
High: $9.14

Volume

350,229 shs

Average Volume

843,529 shs

Market Capitalization

$340.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Sientra?

The following Wall Street sell-side analysts have issued research reports on Sientra in the last year: Canaccord Genuity, Maxim Group, SVB Leerink LLC, William Blair, and Zacks Investment Research.
View the latest analyst ratings for SIEN.

What is the current price target for Sientra?

3 Wall Street analysts have set twelve-month price targets for Sientra in the last year. Their average twelve-month price target is $9.75, suggesting a possible upside of 65.8%. Maxim Group has the highest price target set, predicting SIEN will reach $11.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $8.24 for Sientra in the next year.
View the latest price targets for SIEN.

What is the current consensus analyst rating for Sientra?

Sientra currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SIEN will outperform the market and that investors should add to their positions of Sientra.
View the latest ratings for SIEN.

What other companies compete with Sientra?

Other companies that are similar to Sientra include Inogen, D8, Eargo, Sanara MedTech, Conformis, United Health Products, Invacare, Lakeland Industries, Surgalign, Milestone Scientific, CollPlant Biotechnologies, Alpha Pro Tech, Predictive Oncology, Myomo and ReWalk Robotics.

How do I contact Sientra's investor relations team?

Sientra's physical mailing address is 420 SOUTH FAIRVIEW AVENUE SUITE 200, SANTA BARBARA CA, 93117. The medical instruments supplier's listed phone number is (805) 562-3500 and its investor relations email address is [email protected] The official website for Sientra is www.sientra.com.